Sera Prognostics (NASDAQ:SERA) Shares Down 2.3% – Here’s Why

Sera Prognostics, Inc. (NASDAQ:SERA)’s share price was down 2.3% on Thursday . The company traded as low as $2.01 and last traded at $2.14. Approximately 42,034 shares traded hands during mid-day trading, a decline of 48% from the average daily volume of 81,165 shares. The stock had previously closed at $2.19.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sera Prognostics in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $5.00.

Sera Prognostics Stock Up 0.9%

The business’s 50-day moving average is $1.99 and its two-hundred day moving average is $2.60. The company has a market capitalization of $84.59 million, a P/E ratio of -3.32 and a beta of 0.92.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Sera Prognostics had a negative net margin of 56,385.97% and a negative return on equity of 41.02%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.07 million. Analysts predict that Sera Prognostics, Inc. will post -0.58 EPS for the current year.

Insider Buying and Selling at Sera Prognostics

In related news, CEO Zhenya Lindgardt sold 22,639 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $1.90, for a total transaction of $43,014.10. Following the transaction, the chief executive officer directly owned 741,287 shares of the company’s stock, valued at $1,408,445.30. This trade represents a 2.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 51,133 shares of company stock worth $99,174 over the last 90 days. 11.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Aberdeen Group plc lifted its position in shares of Sera Prognostics by 2.3% during the third quarter. Aberdeen Group plc now owns 2,279,699 shares of the company’s stock valued at $6,976,000 after purchasing an additional 52,332 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Sera Prognostics by 4.6% during the third quarter. Vanguard Group Inc. now owns 1,217,190 shares of the company’s stock valued at $3,725,000 after purchasing an additional 54,008 shares in the last quarter. Citadel Advisors LLC lifted its position in shares of Sera Prognostics by 1.9% during the third quarter. Citadel Advisors LLC now owns 653,746 shares of the company’s stock valued at $2,000,000 after purchasing an additional 12,439 shares in the last quarter. Captrust Financial Advisors increased its holdings in Sera Prognostics by 20.0% during the second quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock worth $1,668,000 after buying an additional 100,366 shares during the last quarter. Finally, Segall Bryant & Hamill LLC purchased a new stake in Sera Prognostics during the first quarter worth about $193,000. 54.64% of the stock is owned by institutional investors.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.